Kalydeco and Facial wasting - a phase IV clinical study of FDA data
Summary:
We study 6,953 people who take Kalydeco (ivacaftor) or have Facial wasting. No report of Facial wasting is found in people who take Kalydeco.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Kalydeco?
Kalydeco has active ingredients of ivacaftor. eHealthMe is studying from 6,652 Kalydeco users. Check the latest studies of Kalydeco.
What is Facial Wasting?
Facial wasting (weakness of facial muscle) is found to be associated with 56 drugs and 240 conditions by eHealthMe. Check the latest studies of Facial wasting.
No report is found.
Do you take Kalydeco and have Facial wasting?
- Check whether Facial wasting is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Kalydeco:
- Kalydeco (6,652 reports)
Facial wasting treatments and more:
- Facial wasting (301 reports)
How severe was Facial wasting and when was it recovered:
Expand to all the drugs that have ingredients of ivacaftor:
Browse all side effects of Kalydeco:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Facial wasting:
Browse all the conditions that are associated with Facial wasting:
How the study uses the data?
The study uses data from the FDA. It is based on ivacaftor (the active ingredients of Kalydeco) and Kalydeco (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Prozac and High Blood Sugar for Men aged 50-59 - a second ago
- Prozac and Hyperglycaemia for Men aged 50-59 - a second ago
- Prozac and High Blood Glucose Level for Men aged 50-59 - 2 seconds ago
- Prozac and High Blood Glucose for Men aged 50-59 - 3 seconds ago
- Prozac and Hyperglycemia for Men aged 50-59 - 3 seconds ago
- Robaxin and Melatonin drug interactions for men aged 60+ - 4 seconds ago
- Kaposi'S Sarcoma and drugs of ingredients of cyclosporine - 4 seconds ago
- Drug interactions of Celebrex and Moxifloxacin - 6 seconds ago
- Neulasta and Methotrexate drug interactions for men aged 60+ - 7 seconds ago
- Methylprednisolone Sodium Succinate and Celebrex drug interactions for women aged 30-39 - 7 seconds ago